Literature DB >> 24045051

Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study.

Wolfgang Weber-Fahr1, Susanne Englisch, Andrea Esser, Nuran Tunc-Skarka, Andreas Meyer-Lindenberg, Gabriele Ende, Mathias Zink.   

Abstract

Phospholipid (PL) metabolism is investigated by in vivo 31P magnetic resonance spectroscopy (MRS). Inconsistent alterations of phosphocholine (PC), phosphoethanolamine (PE), glycerophosphocholine (GPC) and glycerophosphoethanolamine (GPE) have been described in schizophrenia, which might be overcome by specific editing techniques. The selective refocused insensitive nuclei-enhanced polarization transfer (RINEPT) technique was applied in a cross-sectional study involving 11 schizophrenia spectrum disorder patients (SZP) on stable antipsychotic monotherapy and 15 matched control subjects. Metabolite signals were found to be modulated by cerebrospinal fluid (CSF) content and gray matter/brain matter ratio. Corrected metabolite concentrations of PC, GPC and PE differed between patients and controls in both subcortical and cortical regions, whereas antipsychotic medication exerted only small effects. Significant correlations were found between the severity of clinical symptoms and the assessed signals. In particular, psychotic symptoms correlated with PC levels in the cerebral cortex, depression with PC levels in the cerebellum and executive functioning with GPC in the insular and temporal cortices. In conclusion, after controlling for age and tissue composition, this investigation revealed alterations of metabolite levels in SZP and correlations with clinical properties. RINEPT 31P MRS should also be applied to at-risk-mental-state patients as well as drug-naïve and chronically treated schizophrenic patients in order to enhance the understanding of longitudinal alterations of PL metabolism in schizophrenia.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  4th edition; AMARES; ARMS; ATP; BGL; BGM; BM; BPRS; BS; CB; CC; CCTCC; CDSS; CP; CPZ; CSF; CSI; Calgary depression scale for schizophrenia; Cerebellum; D-CSI; DSM-IVR; FC; FEP; GAF; GLM; GM; GPC; GPE; HC; HI; HMPT; IC; Java based magnetic resonance user interface; MWT-B; Magnetic resonance spectroscopy; Mehrfachwahl–Wortschatz–Intelligenztest, version B; PANSS; PC; PDE; PE; PL; PME; Phosphocholine; Phospholipids; Pi; Positive and Negative Syndrome Scale; RINEPT; ROI; SANS; SPM5; SPSS; SZP; Scale for the Assessment of Negative Symptoms; Schizophrenia; Statistical Package for the Social Sciences; TC; VBR; WCST; WM; Wisconsin Card Sorting Test; adenosine triphosphate; advanced method for accurate, robust and efficient signal fitting; at-risk mental state for psychosis; basal ganglia, lateral part; brain matter; brainstem; brief psychiatric rating scale; cerebellum; cerebrospinal fluid; chemical shift imaging; chlorpromazine; cingulate cortex; circular-polarized volume head coil; cortical-cerebellar-thalamic-cortical circuit; diagnostic and statistical manual; first-episode patients; frontal cortex; general linear model; global assessment of functioning; glycerophosphocholine; glycerophosphoethanolamine; gray matter; healthy control; hexamethyl-phosphorous triamide; hippocampus; inorganic phosphate; insular cortex; jMRUI AMARES; phosphocholine; phosphodiester; phosphoethanolamine; phospholipid; phosphomonoester; refocused insensitive nucleus enhancement by polarization transfer; region of interest; revised version; schizophrenia spectrum disorder patients; statistical parametrical mapping, version 5; temporal cortex; thalamus and medial part of basal ganglia; three dimensional chemical shift imaging; ventricle to brain-ratio; white matter

Mesh:

Substances:

Year:  2013        PMID: 24045051     DOI: 10.1016/j.pscychresns.2013.06.011

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Cerebral Energy Status and Altered Metabolism in Early Severe TBI: First Results of a Prospective 31P-MRS Feasibility Study.

Authors:  Daniel Pinggera; Ruth Steiger; Marlies Bauer; Johannes Kerschbaumer; Markus Luger; Ronny Beer; Andreas Rietzler; Astrid E Grams; Elke R Gizewski; Claudius Thomé; Ondra Petr
Journal:  Neurocrit Care       Date:  2021-04       Impact factor: 3.210

2.  Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis.

Authors:  Liisa Leppik; Madis Parksepp; Sven Janno; Kati Koido; Liina Haring; Eero Vasar; Mihkel Zilmer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-02       Impact factor: 5.270

Review 3.  Biomarkers in psychosis: an approach to early identification and individualized treatment.

Authors:  Heline Mirzakhanian; Fiza Singh; Kristin S Cadenhead
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

4.  Bi-directional Mendelian randomization of epithelial ovarian cancer and schizophrenia and uni-directional Mendelian randomization of schizophrenia on circulating 1- or 2-glycerophosphocholine metabolites.

Authors:  Charleen D Adams; Susan L Neuhausen
Journal:  Mol Genet Metab Rep       Date:  2019-11-06

5.  Speciation Study on O-Phosphorylethanolamine and O-Phosphorylcholine: Acid-Base Behavior and Mg2+ Interaction.

Authors:  Donatella Aiello; Massimiliano Cordaro; Anna Napoli; Claudia Foti; Ottavia Giuffrè
Journal:  Front Chem       Date:  2022-03-28       Impact factor: 5.221

6.  Cerebral Energy Status and Altered Metabolism in Early Brain Injury After Aneurysmal Subarachnoid Hemorrhage: A Prospective 31P-MRS Pilot Study.

Authors:  Stephanie Alice Treichl; Wing Mann Ho; Ruth Steiger; Astrid Ellen Grams; Andreas Rietzler; Markus Luger; Elke Ruth Gizewski; Claudius Thomé; Ondra Petr
Journal:  Front Neurol       Date:  2022-02-28       Impact factor: 4.003

7.  3D 31 P MR spectroscopic imaging of the human brain at 3 T with a 31 P receive array: An assessment of 1 H decoupling, T1 relaxation times, 1 H-31 P nuclear Overhauser effects and NAD.

Authors:  Tom H Peeters; Mark J van Uden; Anne Rijpma; Tom W J Scheenen; Arend Heerschap
Journal:  NMR Biomed       Date:  2019-09-13       Impact factor: 4.044

8.  Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study.

Authors:  Dag K Solberg; Håvard Bentsen; Helge Refsum; Ole A Andreassen
Journal:  BMC Psychiatry       Date:  2016-08-25       Impact factor: 3.630

9.  31 P T2 s of phosphomonoesters, phosphodiesters, and inorganic phosphate in the human brain at 7T.

Authors:  Wybe J M van der Kemp; Dennis W J Klomp; Jannie P Wijnen
Journal:  Magn Reson Med       Date:  2017-12-07       Impact factor: 4.668

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.